Xcovery Holdings, Inc.

This phase 3 trial tests whether a new drug called ensartinib works better than the current standard crizotinib for people with ALK-positive non-small cell lung cancer. About 290 participants who have had up to one prior chemotherapy but no prior ALK inhibitor are randomly assign…